



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks

Washington, D.C. 20231 on September 13, 2002

David Saliwanchik

David R. Saliwanchik, Patent Attorney

Patent Application

Docket No. GJE-88

Serial No. 10/070,568

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant(s) : You-Min Feng, You-Shang Zhang
Serial No. : 10/070,568
Conf. No. : 7193
Filed : March 8, 2002
For : Monomeric Analogues of Human Insulin

U.S. Patent and Trademark Office
BOX SEQUENCE, P.O. Box 2327
Arlington, VA 22202

TRANSMITTAL LETTER

Sir:

The Applicants have received a Notification of Defective Response Under 35 U.S.C. 371 from the United States Designated/Elected Office (DO/EO/US), dated September 3, 2002, in the above-referenced patent application. The Notification requests that the applicants comply with Sequence Disclosure Requirements under 37 CFR §1.821 due to a damaged disk.

Transmitted herewith is a Submission of Sequence Listing Under 37 CFR 1.821, Submission of Sequence Listing on paper and in computer readable format (disk), an Submission of Sequence Listing under 37 CFR 1.821-1.825, and a copy of the Notification of Defective Response.

Docket No. GJE-88
Serial No. 10/070,568

The Commissioner is hereby authorized to charge any additional fees that may be required to
Deposit Account No. 19-0065. Two copies of this letter are enclosed.

Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Address : 2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

DRS/la

Attachments: Submission of Sequence Listing under 37 CFR § 1.821;
Sequence Listing on paper and computer readable format (disk); and
Copy of Notification of Defect.